New Data on Ozempic, Mounjaro, the iLet Bionic Pancreas and more | Newsy News #3 | TCOYD

Welcome to the latest episode of Newsy News - your go-to source for the latest updates on diabetes. If you're looking to stay informed on the most recent developments in the diabetes world, you're in the right place. Our expert endocrinologists, Dr. Steve Edelman and Dr. Jeremy Pettus, will break down everything you need to know about the latest advancements in the field. Stay tuned for valuable insights and expert analysis on the most pressing diabetes-related issues.
In this episode, we cover:
1. Mounjaro (tirzepatide) receives FDA approval for obesity treatment under the new trade name Zepbound
2. The FLOW study on Ozempic (semaglutide) for chronic kidney disease ends early due to overwhelming positive effects
3. The iLet Bionic pancreas becomes the 5th FDA-approved hybrid closed loop system for type 1 diabetes management
4. Non-alcoholic steatohepatitis (NASH) receives a confusing nomenclature update to MASH (metabolic dysfunction-associated steatohepatitis)
5. New studies show Ozempic may help curb alcohol and tobacco addictions
6. The topical gel Erexonin gains FDA approval as an over-the-counter treatment for erectile dysfunction.
Whether you're a healthcare professional looking to stay up-to-date or a person living with diabetes wanting to learn more about the latest treatment options, Newsy News has you covered. Subscribe now and never miss an episode!
We've got tons of other great resources on how to live a long and healthy life with diabetes:
Website: tcoyd.org
Blog: tcoyd.org/blog/
Podcast: tcoydthepodcas...
Instagram: / tcoyd
Facebook: / tcoyd
Twitter: / tcoyd
Stay connected!
Sign up for our free monthly e-newsletter here:
bit.ly/3xdqUJ6
T1D Facebook group: / 52436. .
T2D Facebook group: / 38014. .
Facebook group for family and friends of people living with diabetes: / 37586. .
Please consider helping TCOYD continue to improve the lives of those living with diabetes by supporting our educational programs: tcoyd.org/donate
The information contained in or provided through TCOYD content is for general consumer education only, and though it is professional medical advice, always consult your doctor for medical diagnosis and treatment. The use of this information is your full responsibility, with the understanding and agreement that TCOYD is not liable for claim, loss, or damage resulting from its use.
#diabetes #obesity #metabolichealth #type1diabetes #type2diabetes #endocrinology #ozempic #tcoyd #mounjaro #erectiledysfunction